Thomas Stephen Basil 4
4 · Climb Bio, Inc. · Filed Feb 27, 2026
Research Summary
AI-generated summary of this filing
Climb Bio (CLYM) Director Thomas S. Basil Sells Shares
What Happened
Thomas S. Basil, a director of Climb Bio, sold a total of 50,000 shares in two open-market transactions: 33,687 shares on 2026-02-25 for a weighted avg price of $7.00 (proceeds ~$235,964) and 16,313 shares on 2026-02-26 for a weighted avg price of $7.01 (proceeds ~$114,289). Combined proceeds were approximately $350,253. These were outright sales (S), not purchases or option exercises.
Key Details
- Transaction dates: 2026-02-25 (33,687 shares) and 2026-02-26 (16,313 shares).
- Reported prices: weighted averages $7.00 (2/25) and $7.01 (2/26). Individual sale prices ranged from $7.0000 to $7.0600 (2/25) and $7.0000 to $7.0400 (2/26).
- Total shares sold: 50,000; total proceeds: about $350,253.
- Trades executed pursuant to a Rule 10b5‑1 trading plan adopted by Mr. Basil on October 14, 2025 (pre‑arranged plan).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Filing: Form 4 filed 2026-02-27 reporting transactions dated 2026-02-25 — no late filing flag indicated.
Context
Sales under a Rule 10b5‑1 plan are pre-scheduled arrangements that can make insider sales routine and do not necessarily signal a change in the insider’s view of the company. For retail investors, purchases tend to be more informative than routine sales; this filing documents a planned sale that produced modest proceeds (~$350k).
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-25$7.00/sh−33,687$235,964→ 170,970 total - Sale
Common Stock
[F1][F3]2026-02-26$7.01/sh−16,313$114,289→ 154,657 total
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0600, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0400, inclusive.